Although in JAVELIN Bladder 100 the magnitude of the benefit in terms of OS was higher among patients with PD-L1-positive tumor cells (TC) or immune cells (IC) than among patients with PD-L1-negative tumors, the study was not powered to compare outcomes with avelumab in the PD-L1–negative subgroup. The gene discussed is CD274; the disease is neoplasm.